Neuroendokrin daganatok szomatosztatinreceptor- endoradioterápiája: Hazai betegeken szerzett tapasztalatok

Translated title of the contribution: Somatostatin receptor endoradiotherapy of neuroendocrine tumors: Experience in Hungarian patients

Péter Reismann, Zoltán Kender, Gabriella Dabasi, Lídia Sréter, K. Rácz, P. Igaz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Beside conventional therapies for the treatment of neuroendocrine tumors, a new therapeutical approach, peptide receptor radionuclide therapy has been developed recently. There are two important features which make this therapy feasible: somatostatin receptors are strongly over-expressed in most neuroendocrine tumors resulting in a high tumor-to-background ratio and internalization of the somatostatin-receptor complex in neuroendocrine cells. Due to these features, neuroendocrine tumors can be treated with radiolabelled somatostatin analogues. For peptide receptor radionuclide therapy, somatostatin analogues are conjugated to a chelator that can bind a radionuclide. The most frequently used radionuclides for neuroendocrine tumor treatment are the β-emitter Yttrium-90 (90Y) and the β+γ emitter Lutetium-177 (177Lu). Candidates for somatostatin receptor endoradiotherapy are patients with progressive, metastatic, somatostatin- receptor positive neuroendocrine tumors. Many patients have been successively treated with this approach: according to international results major remission can be achieved in 25% of the cases. Although this therapy is still unavailable in Hungary, Hungarian patients can be treated with somatostatin receptor endoradiotherapy with financial support from the National Health Fund in a co-operation with the University of Basel since 2005. During the past 5 years, 51 Hungarian patients have been treated with this therapy. This review briefly summarizes the theoretical background, indications, effectiveness and side effects of somatostatin receptor endoradiotherapy and the authors present the first data obtained from Hungarian patients.

Original languageHungarian
Pages (from-to)392-397
Number of pages6
JournalOrvosi Hetilap
Volume152
Issue number10
DOIs
Publication statusPublished - Mar 1 2011

Fingerprint

Somatostatin Receptors
Neuroendocrine Tumors
Radioisotopes
Peptide Receptors
Therapeutics
Somatostatin
Lutetium
Yttrium
Financial Support
Neuroendocrine Cells
Hungary
Chelating Agents
Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Neuroendokrin daganatok szomatosztatinreceptor- endoradioterápiája : Hazai betegeken szerzett tapasztalatok. / Reismann, Péter; Kender, Zoltán; Dabasi, Gabriella; Sréter, Lídia; Rácz, K.; Igaz, P.

In: Orvosi Hetilap, Vol. 152, No. 10, 01.03.2011, p. 392-397.

Research output: Contribution to journalArticle

Reismann, Péter ; Kender, Zoltán ; Dabasi, Gabriella ; Sréter, Lídia ; Rácz, K. ; Igaz, P. / Neuroendokrin daganatok szomatosztatinreceptor- endoradioterápiája : Hazai betegeken szerzett tapasztalatok. In: Orvosi Hetilap. 2011 ; Vol. 152, No. 10. pp. 392-397.
@article{0cc606f43d1b4985bca07c38b7351d3f,
title = "Neuroendokrin daganatok szomatosztatinreceptor- endoradioter{\'a}pi{\'a}ja: Hazai betegeken szerzett tapasztalatok",
abstract = "Beside conventional therapies for the treatment of neuroendocrine tumors, a new therapeutical approach, peptide receptor radionuclide therapy has been developed recently. There are two important features which make this therapy feasible: somatostatin receptors are strongly over-expressed in most neuroendocrine tumors resulting in a high tumor-to-background ratio and internalization of the somatostatin-receptor complex in neuroendocrine cells. Due to these features, neuroendocrine tumors can be treated with radiolabelled somatostatin analogues. For peptide receptor radionuclide therapy, somatostatin analogues are conjugated to a chelator that can bind a radionuclide. The most frequently used radionuclides for neuroendocrine tumor treatment are the β-emitter Yttrium-90 (90Y) and the β+γ emitter Lutetium-177 (177Lu). Candidates for somatostatin receptor endoradiotherapy are patients with progressive, metastatic, somatostatin- receptor positive neuroendocrine tumors. Many patients have been successively treated with this approach: according to international results major remission can be achieved in 25{\%} of the cases. Although this therapy is still unavailable in Hungary, Hungarian patients can be treated with somatostatin receptor endoradiotherapy with financial support from the National Health Fund in a co-operation with the University of Basel since 2005. During the past 5 years, 51 Hungarian patients have been treated with this therapy. This review briefly summarizes the theoretical background, indications, effectiveness and side effects of somatostatin receptor endoradiotherapy and the authors present the first data obtained from Hungarian patients.",
keywords = "neuroendocrine tumors, peptide receptor radionuclide therapy, somatostatin",
author = "P{\'e}ter Reismann and Zolt{\'a}n Kender and Gabriella Dabasi and L{\'i}dia Sr{\'e}ter and K. R{\'a}cz and P. Igaz",
year = "2011",
month = "3",
day = "1",
doi = "10.1556/OH.2011.29057",
language = "Hungarian",
volume = "152",
pages = "392--397",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "10",

}

TY - JOUR

T1 - Neuroendokrin daganatok szomatosztatinreceptor- endoradioterápiája

T2 - Hazai betegeken szerzett tapasztalatok

AU - Reismann, Péter

AU - Kender, Zoltán

AU - Dabasi, Gabriella

AU - Sréter, Lídia

AU - Rácz, K.

AU - Igaz, P.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Beside conventional therapies for the treatment of neuroendocrine tumors, a new therapeutical approach, peptide receptor radionuclide therapy has been developed recently. There are two important features which make this therapy feasible: somatostatin receptors are strongly over-expressed in most neuroendocrine tumors resulting in a high tumor-to-background ratio and internalization of the somatostatin-receptor complex in neuroendocrine cells. Due to these features, neuroendocrine tumors can be treated with radiolabelled somatostatin analogues. For peptide receptor radionuclide therapy, somatostatin analogues are conjugated to a chelator that can bind a radionuclide. The most frequently used radionuclides for neuroendocrine tumor treatment are the β-emitter Yttrium-90 (90Y) and the β+γ emitter Lutetium-177 (177Lu). Candidates for somatostatin receptor endoradiotherapy are patients with progressive, metastatic, somatostatin- receptor positive neuroendocrine tumors. Many patients have been successively treated with this approach: according to international results major remission can be achieved in 25% of the cases. Although this therapy is still unavailable in Hungary, Hungarian patients can be treated with somatostatin receptor endoradiotherapy with financial support from the National Health Fund in a co-operation with the University of Basel since 2005. During the past 5 years, 51 Hungarian patients have been treated with this therapy. This review briefly summarizes the theoretical background, indications, effectiveness and side effects of somatostatin receptor endoradiotherapy and the authors present the first data obtained from Hungarian patients.

AB - Beside conventional therapies for the treatment of neuroendocrine tumors, a new therapeutical approach, peptide receptor radionuclide therapy has been developed recently. There are two important features which make this therapy feasible: somatostatin receptors are strongly over-expressed in most neuroendocrine tumors resulting in a high tumor-to-background ratio and internalization of the somatostatin-receptor complex in neuroendocrine cells. Due to these features, neuroendocrine tumors can be treated with radiolabelled somatostatin analogues. For peptide receptor radionuclide therapy, somatostatin analogues are conjugated to a chelator that can bind a radionuclide. The most frequently used radionuclides for neuroendocrine tumor treatment are the β-emitter Yttrium-90 (90Y) and the β+γ emitter Lutetium-177 (177Lu). Candidates for somatostatin receptor endoradiotherapy are patients with progressive, metastatic, somatostatin- receptor positive neuroendocrine tumors. Many patients have been successively treated with this approach: according to international results major remission can be achieved in 25% of the cases. Although this therapy is still unavailable in Hungary, Hungarian patients can be treated with somatostatin receptor endoradiotherapy with financial support from the National Health Fund in a co-operation with the University of Basel since 2005. During the past 5 years, 51 Hungarian patients have been treated with this therapy. This review briefly summarizes the theoretical background, indications, effectiveness and side effects of somatostatin receptor endoradiotherapy and the authors present the first data obtained from Hungarian patients.

KW - neuroendocrine tumors

KW - peptide receptor radionuclide therapy

KW - somatostatin

UR - http://www.scopus.com/inward/record.url?scp=79952288642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952288642&partnerID=8YFLogxK

U2 - 10.1556/OH.2011.29057

DO - 10.1556/OH.2011.29057

M3 - Article

C2 - 21354955

AN - SCOPUS:79952288642

VL - 152

SP - 392

EP - 397

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 10

ER -